Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing treatments for central nervous system diseases, provided clinical updates for its investigational programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at their recent R&D Day. The company discussed the results of comprehensive data analysis for TSHA-120, addressing feedback from the U.S..